Fremont, CA-based Zosano Pharma has received $45 million in its second round, bringing its total funding thus far to $90 million. Enterprise Associates, Nomura Phase4 Ventures, HBM BioVentures and ProQuest Investments participated in the round. Zosano is developing a transdermal microprojection delivery system, a small patch and applicator that is designed as an alternative to vaccines administered with needles.
"This second closing supports our continued progress with Zosano's lead program, a PTH patch for treating osteoporosis, which is currently in Phase 2 development," said Cory Zwerling, Zosano's CEO. "Our PTH development program is on track and we are also moving other Zosano activities forward."
- see this release for more
PLUS: Woburn-MA-based BioVex has garnered $35 million in a second round of Series E financing. The company is developing biologics for the treatment and prevention of cancer and infectious disease. The money will fund BioVex's Phase III study of OncoVexGM-CSF for the treatment of melanoma as well as to complete studies in head and neck cancer and pancreatic cancer. Triathlon Medical Ventures led the round. Release